Day: January 21, 2025

# Slow Cooker Bolognese Sauce Recipe: An Italian Delight

Bolognese sauce, also referred to as “ragù alla bolognese,” is a time-honored Italian meat sauce originating from Bologna. Renowned for its robust flavors and hearty consistency, this sauce is a fundamental component of Italian cooking and is typically paired with pasta, polenta, or layered in lasagna. Although traditional methods can be labor-intensive, utilizing a slow cooker streamlines the cooking, allowing the flavors to blend harmoniously over a few hours. In this piece, we will dive into a mouthwatering slow cooker Bolognese sauce recipe ideal for family gatherings or meal prepping.

## Ingredients

To whip up a delectable slow cooker Bolognese sauce, gather the following ingredients:

– **1 lb ground beef** (or a combination of beef and pork for enhanced taste)
– **1 medium onion**, finely chopped
– **2 cloves garlic**, minced
– **1 medium carrot**, finely diced
– **1 celery stalk**, finely diced
– **1 can (14 oz) crushed tomatoes**
– **2 tbsp tomato paste**
– **1 cup beef broth** (or red wine for a richer flavor)
– **1 cup whole milk**
– **1 tsp dried oregano**
– **1 tsp dried basil**
– **Salt and pepper**, to taste
– **Olive oil**, for sautéing
– **Fresh basil or parsley**, for garnish (optional)
– **Grated Parmesan cheese**, for serving (optional)

## Instructions

### Step 1: Sauté the Vegetables

1. **Heat the Olive Oil**: In a skillet over medium heat, pour in a tablespoon of olive oil.
2. **Cook the Aromatics**: Introduce the chopped onion, carrot, and celery into the skillet. Sauté for about 5-7 minutes until the vegetables soften and the onion turns translucent. Mix in the minced garlic and cook for another minute until aromatic.

### Step 2: Brown the Meat

3. **Brown the Ground Meat**: In the same skillet, incorporate the ground beef (or beef and pork blend). Brown the meat, breaking it up with a wooden spoon. This step enhances the sauce’s flavor profile. Drain any excess fat if needed.

### Step 3: Combine Ingredients in the Slow Cooker

4. **Transfer to Slow Cooker**: After browning the meat, move it along with the sautéed vegetables to the slow cooker.
5. **Add Remaining Ingredients**: Stir in the crushed tomatoes, tomato paste, beef broth (or wine), whole milk, oregano, basil, salt, and pepper. Combine everything thoroughly.

### Step 4: Slow Cook the Sauce

6. **Cook**: Cover the slow cooker and set it to low heat. Allow the sauce to simmer for 6-8 hours or on high for 3-4 hours. The longer it cooks, the more intense the flavors become.

### Step 5: Final Touches

7. **Adjust Seasoning**: Approximately 30 minutes before serving, taste the sauce and modify the seasoning with additional salt, pepper, or herbs as necessary.
8. **Serve**: When the sauce is prepared, pour it over your preferred pasta, polenta, or use it as a filling for lasagna. Garnish with fresh basil or parsley and a generous dusting of grated Parmesan cheese.

## Tips for the Perfect Bolognese Sauce

– **Meat Choices**: While ground beef is conventional, feel free to explore various meats like ground turkey, chicken, or even a mix for a distinctive flavor.
– **Wine**: If incorporating wine, select a dry red wine that you enjoy drinking. It enriches the sauce.
– **Milk**: Including milk aids in tenderizing the meat and adds a creamy flavor to the sauce. Make sure not to skip this step!
– **Storage**: This Bolognese sauce can be kept in the refrigerator for up to 4 days or frozen for as long as 3 months. Reheat gently on the stove or in the microwave.

## Conclusion

A slow cooker Bolognese sauce provides a fantastic way to relish an authentic Italian dish with minimal hassle. The slow cooking technique allows the flavors to fully develop, yielding a rich and satisfying sauce that will delight family and friends. Whether served atop pasta, in lasagna, or enjoyed solo as a cozy meal, this Bolognese sauce is a culinary must-try for every home cook. Relish the warmth and comfort of this Italian classic, and enjoy the enticing aromas that will fill your kitchen as it simmers!

**Trump Overturns Biden’s Executive Order on Responsible AI Development: What It Means for the Future of Artificial Intelligence**

In a significant policy shift, former President Donald Trump, during a hypothetical return to office, has overturned President Joe Biden’s executive order on responsible artificial intelligence (AI) development. This decision has sparked widespread debate among policymakers, tech leaders, and ethicists about the future of AI governance in the United States. The move underscores the ongoing tension between fostering innovation and ensuring ethical safeguards in the rapidly evolving field of AI.

### Biden’s Executive Order on Responsible AI Development

President Joe Biden’s executive order, issued during his administration, was widely regarded as a landmark effort to establish a comprehensive framework for the ethical development and deployment of AI technologies. The order emphasized principles such as transparency, accountability, fairness, and the mitigation of risks associated with AI, including bias, privacy violations, and potential misuse.

Key provisions of Biden’s executive order included:

1. **Mandatory Risk Assessments**: Requiring companies and federal agencies to evaluate the potential risks of AI systems before deployment.
2. **Algorithmic Transparency**: Mandating that AI systems used in critical areas, such as healthcare, criminal justice, and hiring, be explainable and auditable.
3. **Equity and Inclusion**: Addressing biases in AI systems to ensure fair treatment of all individuals, regardless of race, gender, or socioeconomic status.
4. **Public-Private Collaboration**: Encouraging partnerships between the government, academia, and the private sector to advance responsible AI research and development.
5. **Global Leadership**: Positioning the U.S. as a leader in setting international standards for ethical AI.

The order was praised by many as a proactive step toward addressing the ethical and societal challenges posed by AI while maintaining America’s competitive edge in the global AI race.

### Trump’s Decision to Overturn the Order

In a dramatic policy reversal, Trump has rescinded Biden’s executive order, citing concerns that the regulations stifled innovation and burdened businesses with unnecessary red tape. In a statement, Trump argued that “America’s technological leadership depends on unleashing the full potential of our innovators, not tying their hands with bureaucratic mandates.”

The new policy under Trump’s administration emphasizes a more laissez-faire approach to AI development, with the following key changes:

1. **Deregulation**: Eliminating mandatory risk assessments and algorithmic transparency requirements for AI systems.
2. **Market-Driven Innovation**: Allowing the private sector to self-regulate and determine best practices for AI development.
3. **Focus on Competitiveness**: Prioritizing investments in AI research and development to maintain U.S. dominance in the global AI market.
4. **Reduced Oversight**: Scaling back federal oversight of AI applications, particularly in industries like finance, healthcare, and defense.

### Implications of the Policy Shift

The decision to overturn Biden’s executive order has far-reaching implications for the future of AI in the United States and beyond. Here are some of the key areas of impact:

#### 1. **Innovation vs. Ethics**
Proponents of Trump’s approach argue that deregulation will accelerate innovation, allowing U.S. companies to compete more effectively with global rivals, particularly China. However, critics warn that the lack of safeguards could lead to the proliferation of biased, opaque, and potentially harmful AI systems.

#### 2. **Public Trust in AI**
Biden’s executive order sought to build public trust in AI by ensuring transparency and accountability. Without these measures, there is a risk that public confidence in AI technologies could erode, particularly if high-profile incidents of AI misuse or failure occur.

#### 3. **Global Leadership**
The U.S. has been a key player in shaping international norms for AI governance. By abandoning Biden’s ethical framework, the U.S. may cede its leadership role to other nations or organizations that prioritize responsible AI development.

#### 4. **Impact on Marginalized Communities**
One of the central goals of Biden’s order was to address systemic biases in AI systems that disproportionately affect marginalized communities. The rollback of these provisions could exacerbate existing inequalities and lead to further discrimination in areas like hiring, lending, and law enforcement.

#### 5. **Economic and Security Risks**
While deregulation may boost short-term innovation, it could also increase the risk of economic and security vulnerabilities. For example, poorly regulated AI systems could be exploited by malicious actors or fail to meet critical safety standards.

### The Path Forward

The debate over Trump’s decision highlights the broader challenge of balancing innovation with ethical responsibility in the AI era. As AI continues to transform industries and societies, the need for thoughtful governance becomes increasingly urgent.

Some experts suggest that a middle ground may be possible—one that combines the flexibility of a market-driven approach with targeted regulations to address specific risks. Others advocate for a more robust international framework to ensure that AI development aligns with shared values and principles.

Ultimately, the future of AI governance

**Absci Collaborates with AMD to Advance AI-Powered Drug Discovery**

In a groundbreaking partnership that underscores the transformative potential of artificial intelligence (AI) in healthcare, Absci Corporation has announced its collaboration with Advanced Micro Devices (AMD) to accelerate AI-powered drug discovery. This strategic alliance brings together Absci’s expertise in AI-driven protein design and AMD’s cutting-edge high-performance computing (HPC) technology, promising to revolutionize the way new therapeutics are discovered and developed.

### The Growing Role of AI in Drug Discovery

The pharmaceutical industry has long grappled with the challenges of time, cost, and complexity in drug discovery. Traditional methods can take over a decade and billions of dollars to bring a single drug to market. AI has emerged as a game-changer, offering the ability to analyze vast datasets, predict molecular interactions, and design novel therapeutics with unprecedented speed and accuracy.

Absci, a leader in AI-powered drug discovery, has been at the forefront of this revolution. The company leverages generative AI and synthetic biology to design and optimize proteins, including therapeutic antibodies and enzymes. By integrating AI with wet-lab capabilities, Absci aims to streamline the drug discovery process, reducing the time and resources required to identify viable drug candidates.

### AMD’s Role in Accelerating AI Workflows

AMD, a global leader in high-performance computing and graphics, is renowned for its advanced processors and GPUs that power some of the world’s most demanding computational workloads. The company’s EPYC™ processors and Radeon™ Instinct GPUs are designed to handle massive datasets and complex algorithms, making them ideal for AI and machine learning applications.

Through this collaboration, Absci will harness AMD’s cutting-edge technology to enhance its AI models and accelerate the discovery of novel therapeutics. AMD’s hardware will enable Absci to process and analyze data at unprecedented speeds, allowing the company to iterate and refine its protein designs more efficiently.

### Key Objectives of the Collaboration

The partnership between Absci and AMD is centered on achieving several key objectives:

1. **Scaling AI Models**: Absci’s generative AI models require significant computational power to simulate protein structures and predict their interactions. AMD’s HPC technology will provide the necessary infrastructure to scale these models, enabling Absci to tackle more complex challenges in drug discovery.

2. **Enhancing Predictive Accuracy**: By leveraging AMD’s advanced processors and GPUs, Absci aims to improve the accuracy of its AI predictions. This will help the company identify high-potential drug candidates with greater confidence, reducing the risk of failure in later stages of development.

3. **Accelerating Time-to-Market**: The integration of AMD’s technology will streamline Absci’s workflows, allowing the company to move from concept to preclinical testing more quickly. This could significantly shorten the timeline for bringing new drugs to market, benefiting patients in need of innovative treatments.

4. **Driving Innovation in Biologics**: Absci specializes in biologics, a class of drugs that includes antibodies, peptides, and other protein-based therapeutics. The collaboration with AMD will enable Absci to push the boundaries of biologics design, exploring new possibilities for treating diseases that were previously considered untreatable.

### Implications for the Pharmaceutical Industry

The Absci-AMD partnership represents a significant step forward for the pharmaceutical industry, which is increasingly embracing AI and HPC to overcome traditional bottlenecks in drug discovery. By combining Absci’s domain expertise with AMD’s technological prowess, the collaboration has the potential to set new benchmarks for speed, efficiency, and innovation in the field.

Moreover, this partnership highlights the growing convergence of biotechnology and computing. As AI continues to evolve, its integration with HPC is expected to unlock new opportunities for personalized medicine, precision therapeutics, and other cutting-edge advancements in healthcare.

### Looking Ahead

The collaboration between Absci and AMD is a testament to the power of interdisciplinary partnerships in driving scientific progress. By leveraging the strengths of both companies, this alliance aims to redefine what is possible in drug discovery, ultimately improving patient outcomes and advancing global health.

As the partnership unfolds, it will be exciting to see how Absci and AMD push the boundaries of AI-powered drug discovery, setting the stage for a new era of innovation in the pharmaceutical industry. With the combined expertise of these two industry leaders, the future of medicine looks brighter than ever.

**DarioHealth Secures $25.6 Million Through Private Placement of Convertible Preferred Stock**

DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company specializing in innovative solutions for chronic condition management, has announced a significant financial milestone. The company successfully raised $25.6 million through a private placement of convertible preferred stock. This strategic funding move is expected to bolster DarioHealth’s growth trajectory and further its mission of revolutionizing chronic disease management through digital health technologies.

### Understanding the Private Placement of Convertible Preferred Stock

Private placement refers to the sale of securities to a select group of accredited investors, institutional investors, or other qualified buyers, rather than through a public offering. In this case, DarioHealth issued convertible preferred stock, a hybrid financial instrument that combines features of both equity and debt. Convertible preferred stock provides investors with fixed dividends and the option to convert their shares into common stock at a predetermined conversion rate.

This financing structure offers several advantages for both the company and its investors. For DarioHealth, it provides access to capital without immediate dilution of common stockholders’ equity. For investors, it offers a relatively secure investment with the potential for equity upside if the company’s stock performs well.

### Strategic Implications of the Funding

The $25.6 million raised in this private placement will enable DarioHealth to accelerate its growth initiatives and expand its market presence. The company has been at the forefront of digital health innovation, offering a comprehensive platform that integrates advanced technology, behavioral science, and data analytics to help individuals manage chronic conditions such as diabetes, hypertension, and musculoskeletal disorders.

The funds are expected to be allocated toward several key areas:

1. **Product Development and Innovation**: DarioHealth can enhance its existing solutions and develop new features to address the evolving needs of patients and healthcare providers. This includes leveraging artificial intelligence (AI) and machine learning (ML) to deliver more personalized and effective care.

2. **Market Expansion**: The company plans to expand its footprint in the U.S. and international markets, targeting employers, health plans, and providers who are increasingly adopting digital health solutions to improve patient outcomes and reduce healthcare costs.

3. **Strategic Partnerships**: DarioHealth has a history of forming partnerships with major healthcare organizations and technology companies. The additional capital will enable the company to pursue new collaborations that can drive adoption of its platform.

4. **Operational Scaling**: As demand for digital health solutions continues to grow, DarioHealth can use the funds to scale its operations, enhance customer support, and invest in marketing and sales efforts.

### The Growing Demand for Digital Health Solutions

DarioHealth’s successful fundraising comes at a time when the digital health industry is experiencing rapid growth. The COVID-19 pandemic accelerated the adoption of telehealth and remote patient monitoring solutions, highlighting the importance of accessible, technology-driven healthcare. According to industry reports, the global digital health market is projected to reach $551 billion by 2027, growing at a compound annual growth rate (CAGR) of 16.5% from 2020.

Chronic diseases, which account for the majority of healthcare costs worldwide, represent a significant opportunity for digital health companies. DarioHealth’s platform addresses this need by providing users with tools to monitor their health, receive personalized insights, and engage in behavior change programs that improve long-term outcomes.

### Investor Confidence in DarioHealth

The successful private placement reflects strong investor confidence in DarioHealth’s business model, leadership team, and growth potential. The company’s innovative approach to chronic disease management has garnered attention from both the healthcare and investment communities. By combining cutting-edge technology with a patient-centric approach, DarioHealth is well-positioned to capitalize on the growing demand for digital health solutions.

### Conclusion

DarioHealth’s $25.6 million private placement of convertible preferred stock marks a pivotal moment in the company’s journey. The additional capital will empower DarioHealth to expand its offerings, reach new markets, and solidify its position as a leader in the digital health space. As the healthcare industry continues to embrace technology-driven solutions, DarioHealth’s innovative platform is poised to make a meaningful impact on the lives of millions of individuals managing chronic conditions.

With this latest funding round, DarioHealth is not only strengthening its financial foundation but also reaffirming its commitment to transforming healthcare through innovation and technology. Investors and stakeholders alike will be watching closely as the company leverages this infusion of capital to drive its next phase of growth.